BH3-mimetics in rational combination therapies to overcome treatment-resistant cancers

Roberts, Andrew W. (Primary Chief Investigator (PCI))
Wei, Andrew (Chief Investigator (CI))
Si Lun Tam, Con (Chief Investigator (CI))
Lindeman, Geoffrey J. (Chief Investigator (CI))
Huang, David C S (Chief Investigator (CI))
Herold, Marco J (Chief Investigator (CI))
Seymour, John Francis (Chief Investigator (CI))
Mason, Kylie (Chief Investigator (CI))
Guthridge, Mark Andrew (Chief Investigator (CI))

Project: Research

Status	Finished
Effective start/end date	22/05/14 → 22/11/19

Funding

Victorian Cancer Agency: A$2,480,792.00

1 Article

A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2– positive metastatic breast cancer
Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., Liew, D., Liu, H. K., Mann, G. B., Moodie, K., Murugasu, A., Pal, B., Roberts, A. W., Rosenthal, M. A., Shackleton, K. & Silva, M. J. & 11 others, Siow, Z. R., Smyth, G. K., Taylor, L., Travers, A., Yeo, B., Yeung, M. M., Bujak, A. Z., Dawson, S. J., Gray, D. H. D., Visvader, J. E. & Lindeman, G. J., Mar 2019, In: Cancer Discovery. 9, 3, p. 354-369 16 p.
Research output: Contribution to journal › Article › Research › peer-review

Open Access
File

110 Citations (Scopus)